Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Spero Therapeutics (SPRO) EBT Margin (2016 - 2025)

Spero Therapeutics (SPRO) has disclosed EBT Margin for 10 consecutive years, with 125.87% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBT Margin rose 339.0% year-over-year to 125.87%, compared with a TTM value of 130.59% through Sep 2025, down 15097.0%, and an annual FY2024 reading of 253.94%, down 297827.0% over the prior year.
  • EBT Margin was 125.87% for Q3 2025 at Spero Therapeutics, down from 12.01% in the prior quarter.
  • Across five years, EBT Margin topped out at 150.89% in Q4 2022 and bottomed at 12200.4% in Q1 2022.
  • Average EBT Margin over 5 years is 1909.46%, with a median of 302.61% recorded in 2024.
  • The sharpest move saw EBT Margin soared 4680767bps in 2021, then plummeted -1193595bps in 2022.
  • Year by year, EBT Margin stood at 177.61% in 2021, then surged by 185bps to 150.89% in 2022, then tumbled by -2206bps to 3177.7% in 2023, then skyrocketed by 91bps to 275.48% in 2024, then soared by 54bps to 125.87% in 2025.
  • Business Quant data shows EBT Margin for SPRO at 125.87% in Q3 2025, 12.01% in Q2 2025, and 236.07% in Q1 2025.